Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Letters to the editor

Elevated fasting blood glucose at admission is associated with poor outcomes in patients with COVID-19

To the Editor:

We read with great interest the research article by Dr Targher et al. in Diabetes & Metabolism entitled ‘Patients with diabetes are at higher risk for severe illness from COVID-19’ [1], published online in May 2020. The authors found that diabetes was an independent high-risk factor for severe coronavirus disease 2019 (COVID-19) infection. However, hyperglycaemia is more common in non-diabetic than in diabetic patients [2] and, thus, deserves more attention in clinical practice. To date, data about the prognostic value of different levels of admission fasting blood glucose (FBG) in patients with COVID-19 are scarce. Therefore, we aimed to explore the association between stratified FBG levels and poor outcomes in patients hospitalized for COVID-19.

A total of 449 patients admitted to six designated hospitals with laboratory-confirmed COVID-19 were enrolled in the study. All cases were diagnosed according to World Health Organization (WHO) interim guidelines [3]. Data on the patients’ demographics, comorbidities, laboratory variables and chest computed tomography (CT) images at admission were collected from 1 January to 31 March 2020. Poor outcomes were defined as composite endpoints including at least one of the following conditions: intensive-care-unit (ICU) admission; respiratory failure requiring mechanical ventilation; shock; and/or death.

To identify risk factors for adverse outcomes, variables with $P < 0.10$ on univariable analyses were included in multivariable logistic regression analyses. Patients were categorized into three groups according to FBG levels: < 6.1 mmol/L (n = 291, 64.8%); 6.1–6.9 mmol/L (n = 52, 11.6%); and ≥ 7.0 mmol/L (n = 106, 23.6%). We used Kaplan–Meier curves to evaluate time from admission to death within 30 days in the three FBG groups.

Our institutional ethics committee approved the study and waived informed consent.

Median age of all enrolled patients was 52 years (interquartile range: 38–64), and 259 (57.7%) were male. A total of 45 (10.6%) patients reported having previous diabetes, of which nine (3.1%) had FBG < 6.1 mmol/L, six (11.5%) had FBG at 6.1–6.9 mmol/L, and 30 (28.3%) had FBG ≥ 7.0 mmol/L. Compared with patients with normal FBG levels, patients with elevated FBG were older and more likely to have comorbidities. On multivariable analyses, patients with FBG at 6.1–6.9 mmol/L [odds ratio (OR): 5.38, 95% confidence interval (CI): 1.18–24.52; $P = 0.030$] had a higher risk of progression to critical illness than those with FBG ≥ 7.0 mmol/L (OR: 3.94, 95% CI: 1.03–15.15; $P = 0.046$; Table 1). Patients with FBG ≥ 7.0 mmol/L had the worst 30-day survival, followed by patients with FBG at 6.1–6.9 mmol/L (76.4% and 84.6%, respectively; $P < 0.001$ by log-rank test).

In conclusion, FBG levels at 6.1–6.9 mmol/L and ≥ 7.0 mmol/L at admission are both independent predictors of poor outcomes in patients with COVID-19. Therefore, serial FBG monitoring should be recommended for patients with COVID-19 infection, even in those with no known previous diabetes. During this pandemic of COVID-19, the timely identification of patients with hyperglycaemia can facilitate early symptomatic treatment to reduce the adverse outcomes of COVID-19 [4].

https://doi.org/10.1016/j.diabet.2020.08.004
1262-3636/© 2020 Elsevier Masson SAS. All rights reserved.

Please cite this article in press as: Liu S, et al. Elevated fasting blood glucose at admission is associated with poor outcomes in patients with COVID-19. Diabetes Metab (2021), https://doi.org/10.1016/j.diabet.2020.08.004
Table 1
Risk factors associated with poor outcomes during hospitalization on univariable and multivariable logistic regression analyses.

|                      | Univariable | Multivariable |
|----------------------|-------------|---------------|
|                      | OR (95% CI) | P             | OR (95% CI) | P     |
| Age (years)          | 1.073 (1.053–1.094) | < 0.001 | 1.058 (1.011–1.108) | 0.015 |
| Gender:              |             |               |             |       |
| Male                 | Reference   | 1.780 (1.054–3.005) | < 0.001 | 2.187 (0.574–8.338) | 0.252 |
| Comorbidities:       |             |               |             |       |
| Hypertension         | 3.679 (2.144–6.314) | < 0.001 | 1.230 (0.939–4.210) | 0.274 |
| Coronary heart disease | 3.150 (1.125–7.490) | 0.009 | 0.891 (0.151–5.277) | 0.899 |
| Diabetes             | 3.898 (2.020–7.521) | < 0.001 | 1.301 (0.303–5.590) | 0.724 |
| Hepatitis            | 1.120 (0.311–4.027) | 0.861 |                       |       |
| Chronic lung disease | 1.938 (0.825–4.533) | 0.129 |                       |       |
| Previous surgery     | 3.608 (1.884–6.510) | < 0.001 | 1.402 (0.302–6.509) | 0.666 |

Laboratory findings:

|                      |             |               |             |       |
| WBC count (<10^9/L)  | 1.225 (1.123–1.337) | < 0.001 | 1.171 (0.416–3.295) | 0.765 |
| Neutrophils (<10^9/L)| 1.308 (1.191–1.436) | < 0.001 | 1.085 (0.389–3.029) | 0.876 |
| Lymphocytes (<10^9/L)| 0.128 (0.066–0.247) | < 0.001 | 1.875 (0.372–9.453) | 0.446 |
| LDH (IU/L)           | 1.010 (1.007–1.012) | < 0.001 | 1.007 (1.001–1.012) | 0.012 |
| Haemoglobin (g/L)    | 1.002 (0.989–1.015) | 0.783 |                       |       |
| Platelets (<10^11/L) | 0.994 (0.990–0.997) | 0.001 | 0.997 (0.989–1.005) | 0.452 |
| Albumin (g/L)        | 0.826 (0.783–0.872) | < 0.001 | 0.921 (0.799–1.061) | 0.254 |
| AST (U/L)            | 1.028 (1.016–1.040) | < 0.001 | 1.005 (0.975–1.036) | 0.750 |
| ALT (U/L)            | 1.003 (0.996–1.011) | 0.383 |                       |       |
| DBIL (μmol/L)        | 1.182 (1.081–1.293) | < 0.001 | 1.007 (0.851–1.191) | 0.938 |
| TBIL (μmol/L)        | 0.935 (0.876–0.998) | 0.044 | 0.913 (0.757–1.101) | 0.340 |
| APPT (s)             | 1.014 (0.974–1.054) | 0.503 |                       |       |
| PT (s)               | 1.037 (0.995–1.081) | 0.082 | 1.046 (1.005–1.090) | 0.027 |
| D-dimer (µg/mL)      | 1.001 (0.999–1.004) | 0.285 |                       |       |
| Creatinine (μmol/L)  | 1.024 (1.013–1.035) | < 0.001 | 1.013 (0.999–1.027) | 0.074 |
| CK (U/L)             | 1.004 (1.002–1.006) | 0.001 | 1.002 (0.998–1.006) | 0.247 |
| CK-MB (U/L)          | 1.076 (1.043–1.110) | < 0.001 | 1.044 (0.984–1.107) | 0.153 |
| hs-CRP (mg/L)        | 1.012 (1.006–1.018) | < 0.001 | 0.978 (0.964–0.992) | 0.002 |
| Procalcitonin (ng/mL)| 1.127 (1.039–1.223) | 0.004 | 1.036 (0.871–1.233) | 0.688 |
| Potassium (mmol/L)   | 0.493 (0.305–0.799) | 0.004 | 0.450 (0.162–1.252) | 0.126 |
| Sodium (mmol/L)      | 0.840 (0.779–0.906) | < 0.001 | 0.945 (0.765–1.169) | 0.604 |
| Chlorine (mmol/L)    | 0.901 (0.854–0.951) | < 0.001 | 0.779 (0.648–0.936) | 0.008 |
| Admission fasting blood glucose | Reference | Reference | Reference | Reference |
| <6.1 mmol/L           |             |               |             |       |
| 6.1–6.9 mmol/L       | 6.534 (3.012–14.176) | < 0.001 | 5.383 (1.182–24.522) | 0.030 |
| ≥7.0 mmol/L          | 11.890 (6.376–22.173) | < 0.001 | 3.944 (1.027–15.145) | 0.046 |
| Computed tomography (CT) score | 0.960 (0.894–1.032) | 0.268 |                       |       |

Each of the five lung lobes was evaluated for degree of involvement, and classified/scored as 0 (0%), 1 (1–25%), 2 (26–50%), 3 (51–75%) or 4 (76–100%); sum severity CT scores of the total lung were obtained by summing the five lobe scores (maximum: 20); CT images were reviewed independently by two radiologists, each with >10 years’ experience; WBC, white blood cell; LDH, lactate dehydrogenase; AST/ALT, aspartate/alanine aminotransferase; TBIL/DBIL/IBIL, total/direct/indirect bilirubin; APPT, activated partial thromboplastin time; PT, prothrombin time; CK, creatine kinase; MR, myocardial band; hs-CRP, high-sensitivity C-reactive protein.

Conflicts of interest

None.

References

[1] Targher G, Mantovani A, Wang X-B, Yan HD, Sun QF, Pan KH, et al. Patients with diabetes are at higher risk for severe illness from COVID-19. Diabetes Metab 2020. http://dx.doi.org/10.1016/j.diabet.2020.05.001 [Online ahead of print].

[2] Wang S, Ma P, Zhang S, Song S, Wang Z, Ma Y, et al. Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia 2020. http://dx.doi.org/10.1007/s00125-020-05209-1 [Online ahead of print].

[3] WHO. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases; Available from www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117. Accessed 18 July 2020 2020.

[4] Zhu L, She ZG, Cheng X, Qi JJ, Zhang XJ, Cai J, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab 2020;31:1068–1077.e3. http://dx.doi.org/10.1016/j.cmet.2020.04.021.

Please cite this article in press as: Liu S, et al. Elevated fasting blood glucose at admission is associated with poor outcomes in patients with COVID-19. Diabetes Metab (2021), https://doi.org/10.1016/j.diabet.2020.08.004